There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Amicus (FOLD) and Y-Mabs Therapeutics Inc (YMAB) with bullish sentiments.
Amicus (FOLD)
In a report released today, Debjit Chattopadhyay from H.C. Wainwright maintained a Buy rating on Amicus, with a price target of $18. The company’s shares closed yesterday at $12.45.
Chattopadhyay noted:
“Valuation and risks to our investment thesis. Our 12-month, $18 price target on shares of Amicus is derived from a 13-year DCF-based, sum-of-the-parts analysis driven by: beta of 1.70; terminal growth rate of 0.5%; risk premium of 4.93%; estimated WACC of 10.8%; and tax rate of 12.5% beginning in FY 2030. 42% each, plus the two Batten disease programs programs at a combined 16%, make up our rNPV. For AT-GAA, we assume a POS of 70%, whereas for CLN6 we assume a 45% POS and assign a 10% POS for CLN3.”
According to TipRanks.com, Chattopadhyay is a 3-star analyst with an average return of 1.4% and a 45.1% success rate. Chattopadhyay covers the Healthcare sector, focusing on stocks such as Global Blood Therapeutics, Voyager Therapeutics Inc, and Autolus Therapeutics Plc.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Amicus with a $21.60 average price target.
See today’s analyst top recommended stocks >>
Y-Mabs Therapeutics Inc (YMAB)
H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Y-Mabs Therapeutics Inc today and set a price target of $40. The company’s shares closed yesterday at $22.86.
Selvaraju said:
“We have assessed Y-mAbs using a discounted cash flow (DCF)-based methodology, which yields a total enterprise value of $1.45B for the company based solely on the future sales of naxitamab and omburtamab.”
According to TipRanks.com, Selvaraju is a 4-star analyst with an average return of 4.4% and a 35.8% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Taro Pharmaceutical Industries Ltd., Biospecifics Technologies Corp, and EyePoint Pharmaceuticals Inc.
Currently, the analyst consensus on Y-Mabs Therapeutics Inc is a Moderate Buy with an average price target of $40, implying a 75.0% upside from current levels. In a report released yesterday, Cowen & Co. also maintained a Buy rating on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
